Clinical Trial Update: Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction. [Phase 4]

View source ↗

Summary

Phase 4 trial comparing LCZ696 (sacubitril/valsartan) to enalapril in chronic heart failure with reduced ejection fraction has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Enalapril (enalapril)
• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Heart Failure With Reduced Ejection Fraction | Phase 4 | Status: COMPLETED | Results posted: 2020-10-09